TipRanks
Go Ultimate55% OFF

Ensysce Biosciences (ENSC) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Pf614 CapsulePostoperative Pain, AcutePhase IIIRecruitingPF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)Sep 16, 2024―
Pf614 Capsule, Nafamostat MesylatePharmacokineticsPhase IRecruitingSingle and Multi-Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)Jul 08, 2024

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ensysce Biosciences, Inc. (ENSC) have in its pipeline
Ensysce Biosciences ENSC is currently developing the following drugs: Pf614 Capsule, Pf614 Capsule, Nafamostat Mesylate. These drug candidates are in various stages of clinical development as the company works toward FDA approval.